English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

CRA3507. 21. Goldberg RM, Sargent DJ, Thibodeau SN, et al. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. J Clin Oncol. 2010;28(suppl 15). Abstract 3508. 22. Jatoi A, Green EM, Rowland KM Jr, Sargent DJ, Alberts SR. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in North Central Cancer Treatment Group Study N0147. Oncology. 2009;77(2):120–123. Affiliations of authors: Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium (ST); Center for Human Genetics O&N1, Katholieke Universiteit Leuven, Leuven, Belgium (ST, ZS); Département de formation et recherche (DFR), Centre Hospitalier Universitaire Vaudois (CHUV), Head Bioinformatics Core Facility (BCF), SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland (MD); Institute of Pathology, Centre HospitalierUniversitaireVaudois (CHUV), Lausanne, Switzerland (FB); Oncosurgery unit, Geneva University Hospital, Geneva,

Microsatellite Instability, Prognosis and Drug Sensitivity of Stage II and III Colorectal Cancer: More Complexity to the Puzzle